Efficacy of sulodexin in diabetics with atherosclerosis obliterans of the lower limbs was assessed from changes in clinical manifestations of intermittent claudication, results of treadmill test, dopplerography of the lower limb vessels, lipidogram, and time course of coagulologic values. Twenty patients with involvement of the lower limb arteries with stages I I-1II according to Fontain were examined. After 10 intramuscular injections of Vessel Due F in a dose of 600 LRU, the drug was administered orally in a dose of 250 LRU twice a day for 12 weeks. Clinical improvement was attained in 88% of patients. The distance of painless walking increased from 152.7+22.2 to 283.6+52.4 m (by 86%), maximal distance from 221.2+29.5 to 376.6+56.9 m (by 70%). Study of changes in coagulologic values over the course of treatment showed increase of activated partial thromboplastin time from 30.7+2.7 to 38.4+1.5 sec (p<0.02), decrease of serum fibrinogen from 4.0+0.1 to 3.2+0.1 g/liter (p<0.003), and increase of thrombin time from 21.7+4.7 to 26.7+3.4 sec (p<0.006). Cholesterol decreased from 6.7+1.0 to 6.27+0.3 mmole/liter (p<.05) and triglycerides showed a tendency to decrease from 1.9+0.23 to 1.7+0.2 mmole/liter (NS). No allergic reactions or side effects were observed during therapy.
Clinical research of angioplasty and stent implantation in the treatment of lower limb atherosclerosis obliterans
